Subscribe To
Marathon digital bounces with bitcoin, ethereum: but will it be enough to buck the trend?
On Nov. 15, Marathon Digital Holdings, Inc (NASDAQ:MARA) plummeted over 27% after the company disclosed it had received a subpoena from the U.S. Secur...
November 19, 2021, 1:19 pm
Marathon digital bounces with bitcoin, ethereum: but will it be enough to buck the trend?
On Nov. 15, Marathon Digital Holdings, Inc (NASDAQ:MARA) plummeted over 27% after the company disclosed it had received a subpoena from the U.S. Secur...
November 19, 2021, 1:19 pm
Marathon digital bounces with bitcoin, ethereum: but will it be enough to buck the trend?
On Nov. 15, Marathon Digital Holdings, Inc (NASDAQ:MARA) plummeted over 27% after the company disclosed it had received a subpoena from the U.S. Secur...
November 19, 2021, 1:19 pm
Cortexyme: a challenging path forward
Cortexyme: A Challenging path Forward...
November 17, 2021, 12:06 am
Cortexyme: a challenging path forward
Cortexyme: A Challenging path Forward...
November 17, 2021, 12:06 am
Cortexyme: a challenging path forward
Cortexyme: A Challenging path Forward...
November 17, 2021, 12:06 am
Behavioral healthcare firm talkspace stock falls as ceo leaves, analyst cut ratings
Baird has downgraded virtual behavioral healthcare company Talkspace Inc (NASDAQ:TALK) to Neutral from Outperform and lowered the price target to ...
November 16, 2021, 1:45 pm
Behavioral healthcare firm talkspace stock falls as ceo leaves, analyst cut ratings
Baird has downgraded virtual behavioral healthcare company Talkspace Inc (NASDAQ:TALK) to Neutral from Outperform and lowered the price target to ...
November 16, 2021, 1:45 pm
Behavioral healthcare firm talkspace stock falls as ceo leaves, analyst cut ratings
Baird has downgraded virtual behavioral healthcare company Talkspace Inc (NASDAQ:TALK) to Neutral from Outperform and lowered the price target to ...
November 16, 2021, 1:45 pm
Chinese state newspaper blasts 'worship of turnover' after alibaba's singles day
The focus of China's Singles' Day shopping festival should shift from a "traffic and sales war" to one of science and technology, a state-backed newsp...
November 11, 2021, 9:53 pm
Chinese state newspaper blasts 'worship of turnover' after alibaba's singles day
The focus of China's Singles' Day shopping festival should shift from a "traffic and sales war" to one of science and technology, a state-backed newsp...
November 11, 2021, 9:53 pm
Chinese state newspaper blasts 'worship of turnover' after alibaba's singles day
The focus of China's Singles' Day shopping festival should shift from a "traffic and sales war" to one of science and technology, a state-backed newsp...
November 11, 2021, 9:53 pm
Novartis' iptacopan meets primary endpoint goal in rare kidney disease trial
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C...
November 4, 2021, 1:45 pm
Novartis' iptacopan meets primary endpoint goal in rare kidney disease trial
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C...
November 4, 2021, 1:45 pm
Novartis' iptacopan meets primary endpoint goal in rare kidney disease trial
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C...
November 4, 2021, 1:45 pm
Regenxbio reveals interim data from diabetic retinopathy gene therapy trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involve...
October 11, 2021, 1:25 pm
Regenxbio reveals interim data from diabetic retinopathy gene therapy trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involve...
October 11, 2021, 1:25 pm
Regenxbio reveals interim data from diabetic retinopathy gene therapy trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involve...
October 11, 2021, 1:25 pm
Pacira biosciences to acquire flexion therapeutics further expanding leadership position in non-opioid pain management
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain p...
October 11, 2021, 7:00 am
Pacira biosciences to acquire flexion therapeutics further expanding leadership position in non-opioid pain management
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain p...
October 11, 2021, 7:00 am